Laboratorios Farmaceuticos Rovi patented an injectable composition for intramuscular implants to treat cancer, particularly breast cancer. The composition includes letrozole, PLA, and DMSO. The drug particle size distribution and polymer solution viscosity are specified in the claim. GlobalData’s report on Laboratorios Farmaceuticos Rovi gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Laboratorios Farmaceuticos Rovi, was a key innovation area identified from patents. Laboratorios Farmaceuticos Rovi's grant share as of February 2024 was 61%. Grant share is based on the ratio of number of grants to total number of patents.
Injectable composition for treating cancer, especially breast cancer
A recently granted patent (Publication Number: US11918682B2) discloses an injectable composition for the treatment of cancer using the aromatase inhibitor letrozole. The composition consists of about 25% of letrozole, with specific particle size distribution criteria, suspended in a polymeric solution made up of DMSO and biodegradable poly(lactic acid) polymer (PLA). The polymeric solution must have a viscosity within a defined range, and the drug is required to be suspended in this solution. Additionally, the PLA used in the composition is irradiated with beta-radiation and end-capped with an ester group.
Furthermore, the patent includes details about a kit for the in situ preparation of the injectable composition and a method for treating cancer using the disclosed composition. The kit contains the drug and polymer in solid form, along with DMSO in separate containers, or in a single container. The method involves administering the composition intramuscularly to achieve a specific release profile of the drug and ensure a suppression of serum estrogens estrone (E1) and estradiol (E2) in the subject. The patent emphasizes the importance of the composition's characteristics in achieving the desired therapeutic effects in cancer treatment, particularly in regulating estrogen levels in the body during the dosing period.
To know more about GlobalData’s detailed insights on Laboratorios Farmaceuticos Rovi, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
